Previous 10 | Next 10 |
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus v...
Vaxart Inc. (VXRT) is expected to report $-0.18 for Q3 2023
2023-11-02 19:37:06 ET Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Conference Call November 2, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO Brant Biehn - SVP and Business Opera...
2023-11-02 16:09:43 ET More on Vaxart Vaxart Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart Financial information for Vaxart For further details see: Vaxart GAAP EPS of -$0.11 beats by $0...
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company’s oral pill vaccine platform now es...
Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it has dosed the first subject in its Phase 1 clinic...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on ...
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on We...
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET. The webcast of ...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...